Inogatran

Last updated
Inogatran
Inogatran.svg
Names
IUPAC name
2-{[(2R)-1-[(2S)-2-[(4-Carbamimidamidopropyl)carbamoyl]piperidin-1-yl]-3-cyclohexyl-1-oxopropan-2-yl]amino}acetic acid
Other names
N-[(1R)-2-Cyclohexyl-1-[[(2S)-2-[(3-guanidinopropyl)carbamoyl]piperidino]carbonyl]
ethyl]glycine
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
PubChem CID
UNII
  • InChI=1S/C21H38N6O4/c22-21(23)25-11-6-10-24-19(30)17-9-4-5-12-27(17)20(31)16(26-14-18(28)29)13-15-7-2-1-3-8-15/h15-17,26H,1-14H2,(H,24,30)(H,28,29)(H4,22,23,25)/t16-,17+/m1/s1
    Key: CDPROXZBMHOBTQ-SJORKVTESA-N
  • NC(=N)NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@@H](CC2CCCCC2)NCC(=O)O
Properties
C21H38N6O4
Molar mass 438.6 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Inogatran (INN) [1] is a low molecular weight peptidomimetic thrombin inhibitor. Inogatran was developed for the potential treatment of arterial and venous thrombotic diseases. [2]

References

  1. ↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 35" (PDF). World Health Organization. p. 13. Retrieved 2 December 2016.
  2. ↑ Teger-Nilsson, AC; Bylund, R; Gustafsson, D; Gyzander, E; Eriksson, U (January 1997). "In Vitro Effects of Inogatran, a Selective Low Molecular Weight Thrombin Inhibitor". Thrombosis Research . 85 (2): 133–45. doi:10.1016/s0049-3848(96)00230-7. PMID   9058487.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.